Axsome Therapeutics (AXSM) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 43.3% versus a gain of 9.1%. Over five years, MDGL leads with a +453.5% price change compared with +324.1% for AXSM. Madrigal Pharmaceuticals is the larger company by market cap ($11.02 billion vs $8.91 billion), about 1.2 times the size.
On valuation, Axsome Therapeutics trades at a lower forward P/E (36.2x vs 49.5x for Madrigal Pharmaceuticals). Axsome Therapeutics converts more of its revenue into profit, with a net margin of -28.7% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | MDGL |
|---|---|---|
| Share price | $170.08 | $476.91 |
| Market cap | $8.91B | $11.02B |
| 1-day change | -1.67% | -2.22% |
| YTD return | -6.88% | -18.10% |
| 1-year return | +43.27% | +9.15% |
| 5-year return | +324.14% | +453.45% |
| Forward P/E | 36.17 | 49.55 |
| EPS (TTM) | $-3.68 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $958.40M |
| Revenue growth (YoY) | +65.55% | +432.05% |
| Net income (latest FY) | $-183.17M | $-288.28M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | -31.31% |
| Net margin | -28.69% | -30.08% |
| 52-week high | $260.19 | $615.00 |
| 52-week low | $119.20 | $393.61 |
| Distance from 52-week high | -34.63% | -22.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.35% | +43.03% |
| Average volume | 712.30K | 289.24K |
| Shares outstanding | 52.38M | 23.10M |
| Employees | 1,346 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed MDGL by 34.1 percentage points over the past year.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +65.55%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
AXSM vs MDGL FAQ
Which is bigger, Axsome Therapeutics or Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $11.02B compared with $8.91B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or MDGL?
AXSM returned +43.27% over the past 12 months, compared with +9.15% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.